MENU
+Compare
BIB
ETF ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$50.52
Change
-$0.03 (-0.06%)
Net Assets
60.58M

BIB stock forecast, quote, news & analysis

Category: @Trading
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BIB with price predictions
Jan 08, 2025

BIB saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for BIB moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 60 similar instances where the indicator exited the overbought zone. In of the 60 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for BIB moved below the 200-day moving average on December 23, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BIB entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIB's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on BIB as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIB just turned positive on January 03, 2025. Looking at past instances where BIB's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology ETF is 6.71B. The market cap for tickers in the group ranges from 29.81M to 208.98B. AZN holds the highest valuation in this group at 208.98B. The lowest valued company is MRNS at 29.81M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 1%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was -22%. ITCI experienced the highest price growth at 33%, while THRD experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was -32%. For the same stocks of the ETF, the average monthly volume growth was -18% and the average quarterly volume growth was 55%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 78
Price Growth Rating: 65
SMR Rating: 88
Profit Risk Rating: 84
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com